Résumé
Frailty has been defined as a state of increased vulnerability as a consequence of deficit accumulation. Frailty screening has not yet been widely implemented into routine nephrology care. Patients with chronic kidney disease (CKD) are at high risk of being frail, and frailty has been associated with worse outcomes in this population. Standard management of CKD, including initiation of renal replacement therapies, may have decreased benefit or potentially cause harm in the presence of frailty, and a variety of interventions for modifying frailty in the CKD population have been proposed. The optimal means of screening for frailty in patients with kidney disease remains unclear. This review highlights the value of frailty screening in CKD by summarizing the outcomes associated with frailty and exploring proposed changes to the management of frail patients with CKD. Finally, we will propose a framework for how to implement frailty screening into standard nephrology care.
| Langue d'origine | English |
|---|---|
| Pages (de-à) | 229-239 |
| Nombre de pages | 11 |
| Journal | International Journal of Nephrology and Renovascular Disease |
| Volume | 12 |
| DOI | |
| Statut de publication | Published - 2019 |
Note bibliographique
Funding Information:Dr. Tennankore has received unrestricted grant funding for research from Astellas, Canada, and Otsuka. Dr. Tennankore has participated in Advisory boards for AstraZeneca and Otsuka. The authors report no other conflicts of interest in this work.
Publisher Copyright:
© 2019 Worthen and Tennankore.
ASJC Scopus Subject Areas
- Nephrology